Skip to main content

Table 4 Association between POAF and underlying medical conditions on admission

From: A double-blind randomised controlled trial on the effect of Tocovid, a tocotrienol-rich capsule on postoperative atrial fibrillation at the National Heart Institute, Kuala Lumpur: an interim blinded analysis

Medical condition

Total*, n (%)

Non-POAF group, n (%)

POAF group, n (%)

χ2

p value

COPD

 Yes

2 (1.7)

2 (100)

0 (0)

1.00a

 No

114 (98.3)

79 (69.3)

35 (30.7)

  

Asthma

 Yes

1 (0.9)

1 (100)

0 (0)

1.00a

 No

115 (99.1)

80 (69.6)

35 (30.4)

  

Hypertension

 Yes

96 (82.8)

67 (69.8)

29 (30.2)

0.000

0.97

 No

20 (17.2)

14 (70.0)

6 (30.0)

  

Diabetes mellitus

 Yes

82 (70.1)

59 (72)

23 (28)

0.952

0.33

 No

35 (29.9)

22 (62.9)

13 (37.1)

  

Hypercholesterolemia

 Yes

97 (85.1)

69 (71.1)

28 (28.90)

1.030

0.31

 No

17 (14.9)

10 (58.8)

7 (41.2)

  

Chronic kidney disease

 Yes

15 (13.0)

10 (66.7)

5 (33.33)

0.77a

 No

100 (87.0)

70 (70.0)

30 (30.0)

  

Current or ex-smoker

 Yes

63 (58.9)

41 (65.1)

22 (34.9)

6.074

0.014*

 No

44 (41.1)

38 (86.4)

6 (13.6)

  

Alcohol intake

 Yes

6 (6.1)

3 (50)

3 (50)

0.173a

 No

93 (93.9)

70 (75.3)

23 (24.)

  
  1. Total n varies slightly for each item due to a small amount of missing data in each
  2. COPD chronic obstructive pulmonary disease
  3. aTest using Fisher Exact Test
  4. *p value significant at p < 0.05 using Chi-Square test